Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Helsinki University Central Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05159245CT.gov The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | — | Recruiting | — | — | — |
NCT04704154CT.gov A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | — | Completed | — | — | — |
NCT02466802CT.gov Study of Regorafenib and Sildenafil for Advanced Solid Tumors | — | Completed | — | — | — |
NCT02398513CT.gov Regorafenib Phase I Study in Mainland Chinese Patients | — | Completed | — | — | — |
NCT02106845CT.gov Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors. | — | Completed | — | — | — |
NCT02042144CT.gov Safety and Effectiveness of Regorafenib | — | Completed | — | — | — |
NCT01973868CT.gov Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination | — | Completed | — | — | — |
NCT01853046CT.gov Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment | — | Completed | — | — | — |
NCT01287598CT.gov BAY73-4506 Probe Substrate Study | — | Completed | — | — | — |
NCT01339104CT.gov Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT01096030CT.gov Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors | — | Completed | — | — | — |
NCT00960258CT.gov Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Regorafenib (this asset) | Helsinki University Central Hospital | P2 | CCC · 55 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Regorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastrointestinal Stromal Tumor | — | P4 | BBB · 73 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
| Colorectal Adenocarcinoma | — | P2 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Regorafenib in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/regorafenib-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →